The prevalence of and the clinical and demographic characteristics associated with high-intensity proton pump inhibitor use

American Journal of Gastroenterology

Volumn 102, Issue 5, 2007, Pages 942-950

  Targownik, Laura E ^a,d   Metge, Colleen ^a,b,c   Roos, Leslie ^b,c   Leung, Stella ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

^d NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PANTOPRAZOLE; PROKINETIC AGENT; PROTON PUMP INHIBITOR; RABEPRAZOLE; SEROTONIN UPTAKE INHIBITOR; SPASMOLYTIC AGENT; WARFARIN;

ADULT; ARTICLE; CANADA; CLINICAL FEATURE; COMORBIDITY; CONSULTATION; CONTROLLED STUDY; DATA BASE; DEMOGRAPHY; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG TREATMENT FAILURE; DRUG USE; FEMALE; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL DISEASE; GASTROINTESTINAL ENDOSCOPY; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; POLYPHARMACY; PREDICTION; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; STANDARD;

ADULT; ANTI-ULCER AGENTS; DEMOGRAPHY; FEMALE; GASTROESOPHAGEAL REFLUX; HUMANS; LOGISTIC MODELS; MALE; MANITOBA; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PROTON PUMPS;

EID: 34247881752     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2007.01106.x     Document Type: Article

References (37)

1. IMS Health, IMS National Sales Perspectives™, 2/2005. Available at : http://www.imshealth.com/ims/portal/front/articleC/0,2777,6599_3665_69890098, 00.html. Accessed March 31, 2006.
2. DeVault KR, Castell DO. American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2005 100 : 190 200.
3. Dean BB, Gano AD Jr., Knight K, et al. Effectiveness of proton pump inhibitors in nonerosive reflux disease. Clin Gastroenterol Hepatol 2004 2 : 656 64.
4. Talley NJ, Vakil N. Practice Parameters Committee of the American College of Gastroenterology. Guidelines for the management of dyspepsia. Am J Gastroenterol 2005 100 : 2324 37.
5. Peura DA. Prevention of nonsteroidal anti-inflammatory drug-associated gastrointestinal symptoms and ulcer complications. Am J Med 2004 117 (suppl 5A 63S 71S.
6. Leontiadis GI, Sharma VK, Howden CW. Systematic review and meta-analysis: Enhanced efficacy of proton-pump inhibitor therapy for peptic ulcer bleeding in Asia - a post hoc analysis from the Cochrane Collaboration. Aliment Pharmacol Ther 2005 21 : 1055 61.
7. Talley NJ, Moore MG, Sprogis A, et al. Randomised controlled trial of pantoprazole versus ranitidine for the treatment of uninvestigated heartburn in primary care. Med J Aust 2002 177 : 423 7.
8. Fass R, Shapiro M, Dekel R, et al. Systematic review: Proton-pump inhibitor failure in gastro-oesophageal reflux disease - where next? Aliment Pharmacol Ther 2005 22 : 79 94.
9. Katz PO, Castell DO, Chen Y, et al. Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: A randomized, three-way crossover study. Aliment Pharmacol Ther 2004 20 : 399 406.
10. Tutuian R, Katz PO, Bochenek W, et al. Dose-dependent control of intragastric pH by pantoprazole, 10, 20 or 40 mg, in healthy volunteers. Aliment Pharmacol Ther 2002 16 : 829 36.
11. Fass R, Murthy U, Hayden CW, et al. Omeprazole 40 mg once a day is equally effective as lansoprazole 30 mg twice a day in symptom control of patients with gastro-oesophageal reflux disease (GERD) who are resistant to conventional-dose lansoprazole therapy - a prospective, randomized, multi-centre study. Aliment Pharmacol Ther 2000 14 : 1595 603.
12. Fass R, Sontag SJ, Traxler B, et al. Treatment of patients with persistent heartburn symptoms: A double-blind, randomized trial. Clin Gastroenterol Hepatol 2006 4 : 50 6.
13. Talley NJ, Lauritsen K. The potential role of acid suppression in functional dyspepsia: The BOND, OPERA, PILOT, and ENCORE studies. Gut 2002 50 (suppl 4 iv36-41.
14. Talley NJ, Meineche-Schmidt V, Pare P, et al. Efficacy of omeprazole in functional dyspepsia: Double-blind, randomized, placebo-controlled trials (the BOND and OPERA studies). Aliment Pharmacol Ther 1998 12 : 1055 65.
15. Pharmacy Benefits Management Strategic Health Group. Contract adherence reports national reports: Q4FY99. Washington, DC : Department of Veterans Affairs, Veterans Health Administration, 2000.
16. Laheij RJ, Sturkenboom MC, Hassing RJ, et al. Risk of community-acquired pneumonia and use of gastric acid suppressive drugs. JAMA 2004 292 : 1955 60.
17. Roos NP, Shapiro E. Revisiting the Manitoba Centre for Health Policy and Evaluation and its population-based health information system. Med Care 1999 37 : JS10 4.
18. Roos NP. Establishing a population data-based policy unit. Med Care 1999 37 : JS15 26.
19. Robinson JR, Young TK, Roos LL, et al. Estimating the burden of disease: Comparing administrative data and self-reports. Med Care 1997 35 : 932 47
20. Huzel L, Roos LL, Anthonisen NR, et al. Diagnosing asthma: The fit between survey and administrative database. Can Respir J 2003 9 : 407 12.
21. Metge CJ, Black C, Peterson S, et al. The population's use of pharmaceuticals. Med. Care 1999 37 (6 suppl JS42 59.
22. Metge CJ, Blanchard JF, Peterson S, et al. Use of pharmaceuticals by inflammatory bowel disease patients: A population-based study. Am J Gastroenterol 2001 96 : 3348 55.
23. Tsai HH, Chapman R, Shepherd A, et al. Esomeprazole 20 mg on-demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: The COMMAND Study. Aliment Pharmacol Ther 2004 20 : 657 65.
24. Bayerdorffer E, Sipponen P, Bigard M, et al. Esomeprazole 20 mg continous versus on demand treatment of patients with endoscopy-negative reflux disease (ENRD). Gut 2004 53 (suppl 4 A106.
25. Starfield B, Weiner J, Mumford L, et al. Ambulatory care groups: A categorization of diagnoses for research and management. Health Serv Res 1991 26 : 53 74.
26. Smith NS, Weiner JP. Applying population-based case mix adjustment in managed care: The Johns Hopkins Ambulatory Care Group system. Manag Care Q 1994 2 : 21 34.
27. Weiner JP, Starfield BH, Steinwachs DM, et al. Development and application of a population-oriented measure of ambulatory care case-mix. Med Care 1991 29 : 452 72.
28. Mustard CA, Derksen S, Berthelot JM, et al. Assessing ecologic proxies for household income: A comparison of household and neighbourhood-level income measures in the study of population health status. Health Place 1999 5 : 157 71.
29. Cooper GS, Chak A, Lloyd LE, et al. The accuracy of diagnosis and procedural codes for patients with upper GI hemorrhage. Gastrointest Endosc 2000 51 : 423 6.
30. Perkins AJ, Kroenke K, Unutzer J, et al. Common comorbidity scales were similar in their ability to predict health care costs and mortality. J Clin Epidemiol 2004 57 : 1040 8.
31. Koloski NA, Talley NJ, Boyce PM. Epidemiology and health care seeking in the functional GI disorders: A population-based study. Am J Gastroenterol 2002 97 : 2290 9.
32. Mohammed I, Nightingale P, Trudgill NJ. Risk factors for gastro-oesophageal reflux disease symptoms: A community study. Aliment Pharmacol Ther 2005 21 : 821 7.
33. Boyce PM, Talley NJ, Burke C, et al. Epidemiology of the functional gastrointestinal disorders diagnosed according to Rome II criteria: An Australian population-based study. Intern Med J 2006 36 : 28 36.
34. Shorr RI, Ray WA, Daugherty JR, et al. Concurrent use of nonsteroidal anti-inflammatory drugs and oral anticoagulants places elderly persons at high risk for hemorrhagic peptic ulcer disease. Arch Intern Med 1993 153 : 1665 70.
35. Armstrong CP, Blower AL. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut 1987 28 : 527 32.
36. Massimo Claar G, Monaco S, Del Veccho Blanco C, et al. Omeprazole 20 or 40 mg daily for healing gastroduodenal ulcers in patients receiving non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 1998 12 : 463 8.
37. Inadomi JM, McIntyre L, Bernard L, et al. Step-down from multiple- to single-dose proton pump inhibitors (PPIs): A prospective study of patients with heartburn or acid regurgitation completely relieved with PPIs. Am J Gastroenterol 2003 98 : 1940 4.